Please login to the form below
lebrikizumab
This page shows the latest lebrikizumab news and features for those working in and with pharma, biotech and healthcare.
Almirall receives CHMP recommendation for lebrikizumab in atopic dermatitis
Almirall has announced that its IL-13 inhibitor lebrikizumab has been recommended by the European Medicines Agency’s human medicines committee to treat moderate-to-severe atopic dermatitis. ... and nearly 70% of patients receiving lebrikizumab combined
Latest news
-
Almirall and Eli Lilly’s lebrikizumab shows continued improvement in atopic dermatitis
corticosteroids, showed that up 73% of patients treated with lebrikizumab experienced improvement or clearance of face or hand dermatitis. ... and commercialisation of lebrikizumab in the US and the rest of the world.
-
Positive results for Almirall’s lebrikizumab in atopic dermatitis published in NEJM and BJD
In clinical trials, patients experienced significantly clearer skin and less interference with sleep due to itch when taking lebrikizumab compared to placebo. ... development and commercialisation of lebrikizumab in the US and the rest of the world.
-
Almirall granted EMA approval for lebrikizumab in atopic dermatitis
This approval] marks the first step of the regulatory process in Europe of lebrikizumab, which we believe has the potential to become a best-in-class treatment for AD. ... and commercialisation of lebrikizumab in the US and the rest of the world, but not
-
Almirall shares positive topline results from atopic dermatitis trials
These studies are part of the clinical development programme for lebrikizumab in AD, assessing over 2, 000 patients. ... Patients involved in the two trials who were treated with lebrikizumab for a year continued to have relief from itching.
-
Lebrikizumab achieves skin clearance in pivotal phase 3 atopic dermatitis trials
a 75% reduction in disease severity at 16 weeks when receiving lebrikizumab monotherapy in the programme. ... The safety profile of the 16-week period was consistent with prior lebrikizumab studies in atopic dermatitis.
More from news
Approximately 8 fully matching, plus 14 partially matching documents found.
Latest Intelligence
-
Pharma deals during August 2014
This brings a much needed boost to its respiratory portfolio, which currently consists of Pulmozyme (cystic fibrosis) and Xolair (severe asthma) and products in clinical development, eg lebrikizumab (severe asthma).
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Contagious Conversations: Exploring Infectious Disease in the Digital Age
- Austrian State Secretary to speak at FlyPharma Europe 2023
- Further data for AstraZeneca/Daichii Sankyo’s Enhertu for breast cancer requested by NICE
- Gritstone Bio receives $433m BARDA contract for COVID-19 vaccine candidate
- EDX Medical Group develops multi-disease 'point-of-care' rapid tests for cancer, infections and cardiovascular conditions
- ScreenPoint Medical to showcase AI software at European scientific meeting
No results were found
PMHub
Innovative Trials
Innovative Trials is a leading global clinical trial patient recruitment company. With over 10 years’ of experience, Innovative Trials deploys...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
